Laura Shawver

Chief Executive Officer at Silverback Therapeutics, Inc.

Laura Shawver

Laura Shawver

Chief Executive Officer at Silverback Therapeutics, Inc.

Overview
Career Highlights

Sugen, Inc.
Silverback Therapeutics, Inc.
Synthorx, Inc.

RelSci Relationships

1998

Number of Boards

15

Birthday

1958

Age

62

Contact Data
Trying to get in touch with Laura Shawver? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Laura Shawver likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Silverback Therapeutics, Inc.

Relationship likelihood: Strong

Founding Partner at 5AM Venture Management LLC

Relationship likelihood: Strong

Chief Executive Officer at Gamida Cell Ltd.

Relationship likelihood: Strong

Global Head, External Innovation at Johnson & Johnson Innovation LLC

Relationship likelihood: Strong

Partner & Founder at Nextech Invest AG

Relationship likelihood: Strong

Former President, Research & Development at Biogen, Inc.

Relationship likelihood: Strong

Executive Vice Chair at San Francisco Conservatory of Music

Relationship likelihood: Strong

Co-Founder at Valence Life Sciences LLC

Relationship likelihood: Strong

Member, Technical Working Group at Center for Medical Technology Policy

Relationship likelihood: Strong

Executive Vice President, Global Head of Research & Development at Sanofi

Relationship likelihood: Strong

Paths to Laura Shawver
Potential Connections via
Relationship Science
You
Laura Shawver
Chief Executive Officer at Silverback Therapeutics, Inc.
Education
PhD in Pharmacology
Memberships
Member
Current

American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA.

Career History
President
1992 - 2002

SUGEN (Sugen) was a drug discovery company focused on development of protein kinase inhibitors. It was founded in 1991, and shut down in 2003, after pioneering protein kinases as therapeutic targets and developing the successful cancer therapy sunitinib (Sutent).

2002 - 2010

Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection.The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force.

Executive in Residence
2010 - 2011

5AM Ventures invests in next-generation life sciences companies located in the US. The firm targets companies operating in the fields of biopharmaceutical, drug delivery technologies and research instruments. They provides financing for early stage and corporate spin-out capital requirements with an investment size ranging from $20 to $30 million and also makes co-investments.

Boards & Committees
Chief Executive Officer & Director
2020 - Current
Member, Board of Directors
2020 - Current
Member, Board of Directors
2017 - Current
Director
2007 - Current
Member, SU2C Scientific Advisory Committee
Current
Member, Scientific Advisory Committee
Current
Political Donations
Transactions
Details Hidden

Synthorx, Inc. raised money in a private placement transaction

Details Hidden

Cleave Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Phenomix Corp. raised money in a private placement transaction

Investments
Details Hidden

Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Laura Shawver. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Laura Shawver's profile does not indicate a business or promotional relationship of any kind between RelSci and Laura Shawver.